Background
Methods
Data source
Statistics
Approval of study protocol and ethics approval
Results
Description of the study sample
Bavaria | Bremen | Hamburg | Lower Saxony | Muenster in North Rhine-Westphalia | Saarland | Schleswig-Holstein | |
---|---|---|---|---|---|---|---|
Total Number of Cases
|
140,249
|
8,032
|
17,974
|
99,448
|
32,644
|
13,954
|
35,274
|
DCO-cases | 14,176 (10.1) | 322 (4.0) | 1,458 (8.1) | 8,682 (8.7) | 1,755 (5.4) | 494 (3.5) | 3,410 (9.7) |
Not histologically confirmed | 15,697 (11.2) | 557 (6.9) | 2,646 (14.7) | 13,002 (13.1) | 2,509 (7.7) | 844 (6.0) | 3,852 (10.9) |
Other than adenocarcinoma | 27,451 (19.6) | 1,439 (17.9) | 4,595 (25.6) | 17,915 (18.0) | 7,682 (23.5) | 3,147 (22.6) | 6,481 (18.4) |
Site: Appendix (C18.1) | 1,946 (1.4) | 112 (1.4) | 224 (1.2) | 1097 (1.1) | 406 (1.2) | 135 (1.0) | 504 (1.4) |
Number of Cases Included for Analyses
|
110,722
|
6,410
|
12,963
|
77,927
|
24,402
|
10,582
|
28,005
|
Sex
| |||||||
Female | 46,050 (41.6) | 3,045 (47.5) | 6,345 (48.9) | 35,431 (45.5) | 11,101 (45.5) | 4,533 (42.8) | 13,023 (46.5) |
Male | 64,672 (58.4) | 3,365 (52.5) | 6,618 (51.1) | 42,496 (54.5) | 13,301 (54.5) | 6,049 (57.2) | 14,982 (53.5) |
Age at Diagnosis
| |||||||
Median age (in years; 25th-75th percentile) | 71.6 (63-79) | 73.2 (65-80) | 72.4 (64-80) | 72.5 (64-80) | 73.1 (64-80) | 71.9 (64-79) | 72.2 (64-79) |
15-34 | 521 (0.5) | 22 (0.3) | 91 (0.7) | 340 (0.4) | 76 (0.3) | 26 (0.2) | 120 (0.4) |
35-39 | 670 (0.6) | 36 (0.6) | 87 (0.7) | 426 (0.5) | 131 (0.5) | 51 (0.5) | 162 (0.6) |
40-49 | 4,848 (4.4) | 210 (3.3) | 539 (4.2) | 2,969 (3.8) | 890 (3.6) | 396 (3.7) | 1,058 (3.8) |
50-54 | 6,002 (5.4) | 248 (3.9) | 574 (4.4) | 3,683 (4.7) | 1,229 (5.0) | 506 (4.8) | 1,204 (4.3) |
55-69 | 37,487 (33.9) | 1,999 (31.2) | 4,144 (32.0) | 25,018 (32.1) | 7,395 (30.3) | 3,632 (34.3) | 9,194 (32.8) |
70+ Years | 61,194 (55.3) | 3,895 (60.8) | 7,528 (58.1) | 45,491 (58.4) | 14,681 (60.2) | 5,971 (56.4) | 16,267 (58.1) |
Cancer Type According to Site
| |||||||
Colon cancer (C18) | 69,301 (62.6) | 3,993 (62.3) | 8,748 (67.5) | 50,449 (64.7) | 15,723 (64.4) | 6,363 (60.1) | 17,853 (63.7) |
Colon proximal (C18.0, C18.2-C18.5) | 34,577 (31.2) | 2,097 (32.7) | 3,599 (27.8) | 24,586 (31.6) | 8,222 (33.7) | 2,778 (26.3) | 9,107 (32.5) |
Colon distal (C18.6-C18.7) | 28,126 (25.4) | 1,617 (25.2) | 3,118 (24.1) | 19,573 (25.1) | 6,158 (25.2) | 2,578 (24.4) | 7,208 (25.7) |
Colon not otherwise specified (C18.8-C18.9) | 6,598 (6.0) | 279 (4.4) | 2,031 (15.7) | 6,290 (8.1) | 1,343 (5.5) | 1,007 (9.5) | 1,538 (5.5) |
Rectal cancer (C19/C20) | 41,421 (37.4) | 2,417 (37.7) | 4,215 (32.5) | 27,478 (35.3) | 8,679 (35.6) | 4,219 (39.9) | 10,152 (36.3) |
Time Period (Year of Diagnosis)
| |||||||
2003-2005 | 21,650 (19.6) | 1,484 (23.2) | 2,296 (17.7) | 16,049 (20.6) | 3,768 (15.4) | 2,342 (22.1) | 5,668 (20.2) |
2006-2008 | 23,940 (21.6) | 1,395 (21.8) | 2,461 (19.0) | 15,801 (20.3) | 5,151 (21.1) | 2,226 (21.0) | 5,694 (20.3) |
2009-2011 | 22,769 (20.6) | 1,272 (19.8) | 2,816 (21.7) | 15,326 (19.7) | 5,326 (21.8) | 2,030 (19.2) | 5,566 (19.9) |
2012-2014 | 21,923 (19.8) | 1,189 (18.5) | 2,739 (21.1) | 15,244 (19.6) | 5,233 (21.4) | 1,957 (18.5) | 5,509 (19.7) |
2015-2017 | 20,440 (18.5) | 1,070 (16.7) | 2,651 (20.5) | 15,507 (19.9) | 4,924 (20.2) | 2,027 (19.2) | 5,568 (19.9) |
Grading
| |||||||
Low grade (G1) | 5,550 (5.2) | 301 (4.9) | 887 (7.6) | 2,799 (3.8) | 2,152 (9.1) | 391 (3.8) | 1,722 (6.5) |
Intermediate (G2) | 81,674 (77.1) | 4,980 (80.6) | 8,181 (70.3) | 56,210 (76.1) | 16,758 (70.7) | 8,157 (80.0) | 20,154 (75.8) |
High grade (G3/G4) | 18,756 (17.7) | 897 (14.5) | 2,566 (22.1) | 14,875 (20.1) | 4,804 (20.3) | 1,644 (16.1) | 4,709 (17.7) |
UICC (Union for International Cancer Control) Stage
| |||||||
I | 17,638 (15.9) | 652 (10.2) | 1,083 (8.4) | 6,771 (8.7) | 2,670 (10.9) | 799 (7.6) | 3,595 (12.8) |
II | 22,013 (19.9) | 896 (14.0) | 1,763 (13.6) | 10,207 (13.1) | 3,612 (14.8) | 998 (9.4) | 5,071 (18.1) |
III | 21,448 (19.4) | 967 (15.1) | 2,103 (16.2) | 12,216 (15.7) | 3,491 (14.3) | 1,049 (9.9) | 5,388 (19.2) |
IV | 20,399 (18.4) | 1,143 (17.8) | 2,600 (20.1) | 10,318 (13.2) | 3,532 (14.5) | 1,769 (16.7) | 5,137 (18.3) |
Unknown | 29,224 (26.4) | 2,752 (42.9) | 5,414 (41.8) | 38,415 (49.3) | 11,097 (45.5) | 5,967 (56.4) | 8,814 (31.5) |
Incidence trends over time according to site, sex and age at diagnosis
Population | Stage | Annual Incidence Rate per 100,000 During Early Screening Phase (2003-2005) | Most Recent Annual Incidence Rate per 100,000 (2015-2017) | Absolute Difference in Rates | Relative Difference in Rates (%) | APC | 95% CI |
---|---|---|---|---|---|---|---|
Colorectal Cancer (C18-C20)
| |||||||
Total Population
| All Stages | 41.9 | 34.9 | -7.0 | -16.7% | 2003-2007: 0.4% | [-1; 1.8] |
2007-2017: -2.2% | [-2.5; -1.8] | ||||||
Early Stage | 17.4 | 15.3 | -2.0 | -11.7% | 2003-2017: -1% | [-1.3; -0.7] | |
Late Stage | 24.5 | 19.6 | -5.0 | -20.2% | 2003-2006: 1.9% | [-1; 4.8] | |
2006-2017: -2.7% | [-3; -2.3] | ||||||
15-34 Years
| All Stages | 0.9 | 1.4 | 0.6 | 65.7% | 2003-2017: 4.3% | [3.3; 5.3] |
Early Stage | 0.3 | 0.5 | 0.2 | 77.6% | 2003-2017: 5.7% | [3; 8.5] | |
Late Stage | 0.6 | 0.9 | 0.3 | 59.5% | 2003-2017: 3.6% | [2.2; 5] | |
35-39 Years
| All Stages | 4.7 | 5.2 | 0.5 | 10.1% | 2003-2017: 1.4% | [0.2; 2.6] |
Early Stage | 1.5 | 1.8 | 0.3 | 20.5% | 2003-2017: 2.4% | [0.5; 4.4] | |
Late Stage | 3.2 | 3.4 | 0.2 | 5.5% | 2003-2017: 0.8% | [-0.7; 2.4] | |
40-49 Years
| All Stages | 14.7 | 16.2 | 1.5 | 10.2% | 2003-2017: 0.7% | [0; 1.3] |
Early Stage | 5.7 | 6.1 | 0.4 | 7.7% | 2003-2017: 0.8% | [0.1; 1.5] | |
Late Stage | 9.0 | 10.1 | 1.0 | 11.8% | 2003-2017: 0.6% | [-0.3; 1.5] | |
50-54 Years
| All Stages | 42.4 | 39.6 | -2.8 | -6.5% | 2003-2008: 1.5% | [0.3; 2.7] |
2008-2012: -3.8% | [-6.4; -1.2] | ||||||
2012-2017: 0.8% | [-0.4; 2] | ||||||
Early Stage | 15.7 | 15.9 | 0.2 | 1.3% | 2003-2017: -0.1% | [-0.9; 0.7] | |
Late Stage | 26.6 | 23.7 | -2.9 | -11.1% | 2003-2008: 1.5% | [-0.9; 4] | |
2008-2012: -5.3% | [-10.3; -0.1] | ||||||
2012-2015: 2.9% | [-7.6; 14.6] | ||||||
2015-2017: -4% | [-13.9; 6.9] | ||||||
55-69 Years
| All Stages | 129.3 | 95.7 | -33.6 | -26.0% | 2003-2008: -1.3% | [-2; -0.5] |
2008-2011: -4.6% | [-7.7; -1.3] | ||||||
2011-2017: -2.2% | [-2.8; -1.7] | ||||||
Early Stage | 54.7 | 40.4 | 0.2 | 77.6% | 2003-2017: -2.6% | [-2.9; -2.2] | |
Late Stage | 74.6 | 55.3 | 0.3 | 59.5% | 2003-2006: -0.1% | [-3.6; 3.5] | |
2006-2017: -3.1% | [-3.6; -2.6] | ||||||
70+ Years
| All Stages | 262.5 | 222.2 | -40.2 | -15.3% | 2003-2007: 1.5% | [-0.3; 3.3] |
2007-2017: -2.3% | [-2.7; -1.8] | ||||||
Early Stage | 109.8 | 106.4 | 0.3 | 20.5% | 2003-2007: 1.7% | [-0.9; 4.3] | |
2007-2017: -0.9% | [-1.5; -0.2] | ||||||
Late Stage | 152.7 | 115.9 | 0.2 | 5.5% | 2003-2005: 3.6% | [-1.5; 9] | |
2005-2008: -1% | [-5.9; 4.2] | ||||||
2008-2017: -3.5% | [-3.9; -3] | ||||||
Colon Cancer (C18)
| |||||||
Total Population
| All Stages | 25.8 | 21.7 | -4.1 | -15.9% | 2003-2007: 0.1% | [-1.6; 1.8] |
2007-2017: -2% | [-2.4; -1.6] | ||||||
Early Stage | 10.8 | 10.2 | -0.5 | -5.0% | 2003-2017: -0.4% | [-0.8; -0.1] | |
Late Stage | 15.0 | 11.5 | -3.6 | -23.7% | 2003-2006: 0.9% | [-1.9; 3.8] | |
2006-2017: -2.9% | [-3.3; -2.6] | ||||||
15-34 Years
| All Stages | 0.5 | 0.8 | 0.3 | 47.8% | 2003-2017: 3.3% | [2.1; 4.5] |
Early Stage | 0.2 | 0.3 | 0.1 | 52.6% | 2003-2017: 4.2% | [0.7; 7.8] | |
Late Stage | 0.4 | 0.5 | 0.2 | 44.6% | 2003-2017: 2.7% | [0.9; 4.6] | |
35-39 Years
| All Stages | 2.9 | 2.6 | -0.3 | -10.2% | 2003-2017: 0.3% | [-1.7; 2.5] |
Early Stage | 0.9 | 0.9 | 0.0 | 2.6% | 2003-2017: 0.3% | [-1.7; 2.5] | |
Late Stage | 2.0 | 1.7 | -0.3 | -15.7% | 2003-2017: -0.6% | [-2.6; 1.5] | |
40-49 Years
| All Stages | 7.9 | 8.7 | 0.9 | 10.9% | 2003-2017: 0.6% | [-0.1; 1.4] |
Early Stage | 3.1 | 3.5 | 0.4 | 13.9% | 2003-2017: 1.1% | [0.3; 2] | |
Late Stage | 4.8 | 5.2 | 0.4 | 9.3% | 2003-2017: 0.3% | [-0.9; 1.4] | |
50-54 Years
| All Stages | 22.5 | 21.3 | -1.3 | -5.7% | 2003-2009: 0.8% | [-0.5; 2] |
2009-2012: -6.3% | [-12.9; 0.8] | ||||||
2012-2017: 2.7% | [1.1; 4.4] | ||||||
Early Stage | 8.4 | 9.6 | 1.2 | 13.9% | 2003-2005: -6.9% | [-20.1; 8.4] | |
2005-2008: 7.9% | [-7.3; 25.7] | ||||||
2008-2015: -2.5% | [-5; 0.1] | ||||||
2015-2017: 15.7% | [-0.6; 34.8] | ||||||
Late Stage | 14.2 | 11.7 | -2.4 | -17.2% | 2003-2008: 0.6% | [-3.2; 4.5] | |
2008-2012: -7.1% | [-14.8; 1.2] | ||||||
2012-2015: 5.6% | [-11; 25.3] | ||||||
2015-2017: -6.2% | [-20.9; 11.4] | ||||||
55-69 Years
| All Stages | 75.7 | 56.0 | -19.7 | -26.0% | 2003-2008: -1.6% | [-2.7; -0.5] |
2008-2011: -4.5% | [-9.1; 0.4] | ||||||
2011-2017: -2% | [-2.9; -1.2] | ||||||
Early Stage | 32.4 | 25.6 | 0.4 | 13.9% | 2003-2017: -2% | [-2.3; -1.7] | |
Late Stage | 43.3 | 30.4 | 0.4 | 9.3% | 2003-2006: -0.5% | [-3.6; 2.7] | |
2006-2012: -4.3% | [-5.7; -3] | ||||||
2012-2017: -2.1% | [-3.5; -0.7] | ||||||
70+ Years
| All Stages | 178.8 | 155.1 | -23.6 | -13.2% | 2003-2006: 2.3% | [-1.1; 5.9] |
2006-2017: -1.8% | [-2.3; -1.4] | ||||||
Early Stage | 74.9 | 77.6 | 0.4 | 13.9% | 2003-2006: 2.5% | [-1.8; 7] | |
2006-2017: -0.1% | [-0.7; 0.5] | ||||||
Late Stage | 103.8 | 77.5 | 0.4 | 9.3% | 2003-2006: 2.4% | [-1.1; 6] | |
2006-2017: -3.3% | [-3.8; -2.9] | ||||||
Rectal Cancer (C19/C20)
| |||||||
Total Population
| All Stages | 16.1 | 13.2 | -2.9 | -18.0% | 2003-2007: 1% | [-0.8; 2.8] |
2007-2017: -2.5% | [-2.9; -2.1] | ||||||
Early Stage | 6.6 | 5.1 | -1.5 | -22.7% | 2003-2017: -2.1% | [-2.5; -1.7] | |
Late Stage | 9.5 | 8.1 | -1.4 | -14.8% | 2003-2008: 1.3% | [-0.2; 2.7] | |
2008-2017: -2.7% | [-3.2; -2.1] | ||||||
15-34 Years
| All Stages | 0.3 | 0.6 | 0.3 | 97.1% | 2003-2017: 5.9% | [4.4; 7.5] |
Early Stage | 0.1 | 0.2 | 0.1 | 121.9% | 2003-2017: 7.6% | [4.4; 10.9] | |
Late Stage | 0.2 | 0.4 | 0.2 | 84.5% | 2003-2017: 5% | [3; 7.1] | |
35-39 Years
| All Stages | 1.9 | 2.6 | 0.8 | 41.5% | 2003-2017: 2.7% | [0.7; 4.7] |
Early Stage | 0.6 | 0.9 | 0.3 | 46.4% | 2003-2017: 2.7% | [0.7; 4.7] | |
Late Stage | 1.3 | 1.7 | 0.5 | 39.1% | 2003-2017: 2.8% | [0.9; 4.7] | |
40-49 Years
| All Stages | 6.8 | 7.5 | 0.6 | 9.2% | 2003-2017: 0.7% | [0; 1.4] |
Early Stage | 2.6 | 2.6 | 0.0 | 0.4% | 2003-2017: 0.4% | [-0.5; 1.3] | |
Late Stage | 4.3 | 4.9 | 0.6 | 14.5% | 2003-2017: 0.9% | [-0.1; 1.9] | |
50-54 Years
| All Stages | 19.8 | 18.4 | -1.5 | -7.5% | 2003-2007: 2.2% | [-0.7; 5.1] |
2007-2017: -1.7% | [-2.4; -1] | ||||||
Early Stage | 7.3 | 6.4 | -1.0 | -13.2% | 2003-2017: -1.1% | [-2; -0.2] | |
Late Stage | 12.5 | 12.0 | -0.5 | -4.2% | 2003-2017: -0.7% | [-1.5; 0] | |
55-69 Years
| All Stages | 53.7 | 39.7 | -13.9 | -26.0% | 2003-2007: -0.7% | [-2.9; 1.6] |
2007-2017: -3.2% | [-3.7; -2.6] | ||||||
Early Stage | 22.3 | 14.8 | 0.0 | 0.4% | 2003-2017: -3.4% | [-3.9; -2.9] | |
Late Stage | 31.4 | 24.9 | 0.6 | 14.5% | 2003-2007: 0.7% | [-1.9; 3.4] | |
2007-2017: -2.9% | [-3.5; -2.3] | ||||||
70+ Years
| All Stages | 83.7 | 67.1 | -16.6 | -19.9% | 2003-2008: 1.2% | [-0.3; 2.7] |
2008-2017: -3.3% | [-3.8; -2.7] | ||||||
Early Stage | 34.9 | 28.7 | 0.0 | 0.4% | 2003-2007: 1.5% | [-1.6; 4.8] | |
2007-2017: -2.5% | [-3.3; -1.8] | ||||||
Late Stage | 48.8 | 38.4 | 0.6 | 14.5% | 2003-2008: 1.6% | [-0.1; 3.3] | |
2008-2017: -3.7% | [-4.3; -3] |